The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -12,980 | -4,162 | -8,169 | -26,095 |
| Depreciation and amortization | 103 | 108 | 105 | 274 |
| Accretion of debt discount and debt issuance costs | 233 | 230 | 249 | 465 |
| Stock-based compensation expense | 2,853 | 2,549 | 2,420 | 8,085 |
| Allowance (benefit) for credit losses | -127 | 101 | -33 | 61 |
| Provision (benefit) for excess and obsolete inventories | -28 | 3 | 21 | -24 |
| Noncash operating lease expense | 116 | 130 | 127 | 241 |
| Loss on disposal of property and equipment | - | 0 | -4 | - |
| Noncash loss on debt extinguishment | - | 0 | 0 | 0 |
| Change in fair value of common stock warrants | - | 11 | - | - |
| Accounts receivable | 722 | 102 | 98 | -1,112 |
| Inventory | -788 | -214 | 1,791 | -135 |
| Prepaid expenses and other current assets | - | -240 | 1,127 | -201 |
| Other noncurrent liabilities | - | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 690 | - | - | - |
| Other noncurrent assets | -102 | 16 | 207 | -73 |
| Accounts payable | 143 | -398 | -335 | 385 |
| Accrued compensation | -2,383 | -118 | 965 | -4,453 |
| Accrued and other current liabilities | 5,563 | -617 | -850 | 392 |
| Net cash used in operating activities | -7,029 | -1,827 | -8,719 | -19,148 |
| Purchases of property and equipment | 60 | -156 | 170 | 210 |
| Net cash used in investing activities | -60 | 156 | -170 | -210 |
| Net proceeds from hercules loan agreement | - | 0 | 0 | 0 |
| Repayment of midcap loan agreement | - | 0 | 0 | 0 |
| Debt issuance costs | - | 0 | 0 | 0 |
| Proceeds from employee stock purchase plan purchases | - | 325 | -1 | 434 |
| Taxes paid on net share settlement of restricted stock units | -11 | -3 | -1 | -54 |
| Proceeds from exercise of common stock options | 99 | 943 | 27 | 121 |
| Net cash provided by financing activities | 88 | 1,265 | 25 | 501 |
| Net change in cash, cash equivalents, and restricted cash | -7,001 | -406 | -8,864 | -18,857 |
| Cash, cash equivalents, and restricted cash at beginning of period | 92,230 | 92,636 | 120,357 | - |
| Cash, cash equivalents, and restrcited cash at end of period | 85,229 | 92,230 | 92,636 | - |
Sight Sciences, Inc. (SGHT)
Sight Sciences, Inc. (SGHT)